Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice
Lebrikizumab demonstrated favorable real-world effectiveness and safety over 24 weeks in patients with moderate-to-severe AD, supporting its use in routine clinical practice.
Authors
- Eggert Stockfleth (ORCID: https://orcid.org/0000-0002-1922-9062)
- Daniel Myszkowski
- Effimia Poungoura
- Nikolaos Stavropoulos
- Vasileios Dervenis
Institutions
- University Hospitals of the Ruhr-University of Bochum (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1007/s13555-025-01630-9
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00